DigiNepal

ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer

Oncology Research · Tian Zeng, Qingxi Luo, Li Yang et al. · 2026

  • EnglishRead in your language
  • CitedEvery fact sourced
  • Ad-freeNo ads, no tracking

Quick facts

Author
Tian Zeng, Qingxi Luo, Li Yang, Feifan Hou, Yongqi Zhao, Xueru Liu, Ni Jiang, Juan Zou ref
Published
ref
Publisher
Tech Science Press ref
Journal
Oncology Research ref

Questions

Who wrote ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer?
ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer was written by Tian Zeng, Qingxi Luo, Li Yang, Feifan Hou.
When was ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer first published?
ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer was first published in 2026.

Sources

  1. Publisher record (DOI, via Crossref)

Last updated · facts checked 13 November 2026

Cite this page

"ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer". DigiNepal. Last updated 13 November 2026. https://diginpl.com/books/paper-or-2026-084046. Retrieved 14 November 2026.

Machine-readable versions: JSON · Markdown

Open-access publication. Read it free at the publisher: https://doi.org/10.32604/or.2026.084046.

← Books